Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromfenac vs Placebo for Post-Cataract Inflammation
NCT00198445Phase 3Completed
- Sponsor
- Bausch + Lomb
- Start
- May 2003
- Primary completion
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ocular inflammation comparing Bromfenac with Placebo (2 arms). Primary endpoint: Ocular Inflammation Score at Day 15. Started May 2003; status: completed.
02
Drugs
bromfenac sodium
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00198445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198445.